10-Q · May 13, 2026
Lucid Diagnostics reported a revenue increase to approximately $1.3 million for Q4 2026, compared to $0.8 million in the same quarter last year, reflecting a notable uptick in service demand. However, the company…
Earnings analysis · 10-Q
LUCD earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Lucid Diagnostics delivered improving Q2 operating trends, with revenue up 26.7% year over year to $1.474 million, gross margin improving to approximately 2.0%, and diluted EPS improving sequentially to $(0.08) from…
Read full summary
Lucid Diagnostics delivered improving Q2 operating trends, with revenue up 26.7% year over year to $1.474 million, gross margin improving to approximately 2.0%, and diluted EPS improving sequentially to $(0.08) from $(0.17). However, operating expenses remained $14.275 million against $1.474 million of revenue, producing a $12.801 million operating loss, while six-month operating cash burn was $23.398 million. Management continues to disclose substantial doubt about going concern, remains dependent on reimbursement expansion and external financing, and faces a near-term Medicare-related debt waiver expiration on August 22, 2026.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.08
- Segment
- One reportable segment: consolidated EsoGuard/EsoCheck diagnostic testing operations. Q2 2026 revenue was $1.474 million versus $1.163 million in Q2 2025.
What stood out
-
Revenue grew 26.7% year over year
Q2 2026 revenue increased to $1.474 million from $1.163 million in Q2 2025, a $0.311 million or 26.7% increase. Revenue was also up from $1.163 million in Q1 2026.
-
Gross margin turned positive
Gross margin improved to approximately 2.0% in Q2 2026, based on $1.474 million of revenue and $1.445 million of cost of revenue, versus negative 34.4% in Q2 2025 and negative 29.4% in Q1 2026.
-
EPS improved sequentially
Diluted EPS was $(0.08), unchanged from Q2 2025 but improved from $(0.17) in Q1 2026. Net loss attributable to common stockholders declined to $14.715 million from $7.888 million in the prior-year quarter only after reflecting $3.028 million of preferred-stock dividends in Q2 2026 versus $3.449 million in Q2 2025.
-
First positive coverage policy secured
The company secured its first positive laboratory benefit manager coverage policy in July 2026, under which EsoGuard is considered medically necessary for patients meeting American College of Gastroenterology screening criteria.
-
Financing provided $22.3 million
The April registered direct offering generated approximately $16.8 million of net proceeds from 18.0 million shares, while the ATM generated approximately $5.3 million of net proceeds from 4,161,747 shares during the six months ended June 30, 2026.
-
Financing largely offset cash burn
Six-month operating cash flow was negative $23.398 million and equipment purchases were $0.236 million, implying approximately $23.634 million of cash burn before financing. Financing activities provided $22.333 million, limiting the six-month cash decline to $1.301 million.
What to watch
-
Going-concern uncertainty persists
Management disclosed substantial doubt about the company's ability to continue as a going concern within one year. At June 30, 2026, cash was $33.404 million, six-month net loss attributable to common stockholders was $38.343 million, and operating cash flow used was $23.398 million.
-
Debt and Medicare waiver risk
The 2024 Convertible Notes had $21.975 million of face-value principal, a 12.0% stated interest rate, and a $23.500 million fair value at June 30, 2026. A waiver relating to the required positive Medicare decision only covered the period through August 22, 2026.
-
Financing and dilution exposure
The company remains dependent on equity and debt financing: it issued 18.0 million shares in the April offering and sold 4,161,747 ATM shares in the first half. In addition, 22,304,671 common shares remained in abeyance at June 30, 2026, creating potential future dilution.
Management's outlook
No explicit numeric revenue or EPS guidance was provided. Management expects recurring losses and negative operating cash flow, and stated that operations will continue to be funded through debt and/or equity financings or refinancing existing debt.
Earlier filings 4
10-K · March 25, 2026
Lucid Diagnostics (fiscal year ended 2025) showed modest commercial traction with revenue rising to $4,828,000 in 2025 from $3,976,000 in 2024 (an increase of $852,000, or ~21.4%), and sequential improvements in gross…
10-Q · August 12, 2025
Lucid Diagnostics reported Q2 revenue of $1.163 million (up $0.187 million vs. $0.976 million in Q2 2024) and GAAP net loss per share improved to $(0.08) from $(0.23) a year ago. Gross margin materially improved to…
10-K · March 24, 2025
Lucid Diagnostics presents a commercial-stage esophageal precancer screening test (EsoGuard) paired with a swallowable cell-collection device (EsoCheck) with strong analytical validation (e.g., ~97% analytical…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.